Examples of using Vimizim in English and their translations into Portuguese
{-}
-
Colloquial
-
Official
-
Medicine
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Official/political
following 6 months of treatment, Vimizim was shown to be effective at improving the distance patients could walk in six minutes,
all Healthcare Professionals who are expected to use and/or prescribe Vimizim are provided with an Educational pack.
the disease is considered‘rare', and Vimizim was designated an‘orphan medicine'(a medicine used in rare diseases)
Why is Vimizim approved?
If you are treated with Vimizim, you may develop infusion reactions.
The infusion bag is gently rotated to ensure proper distribution of Vimizim.
Vimizim is slowly added to the infusion bag using care to avoid agitation.
Before withdrawing Vimizim from the vial, each vial is visually inspected for particulate matter and discoloration.
The company will also set up a registry to assess the long-term benefits and risks of Vimizim.
Vimizim should not be mixed with other medicinal products in the same infusion, except for those mentioned below.
Before receiving Vimizim, the patient should be given a medicine to prevent an allergic reaction to Vimizim. .
it is preferable to avoid the use of Vimizim during pregnancy, unless clearly necessary.
Administration of Vimizim should be carried out by an appropriately trained healthcare professional with the ability to manage medical emergencies.
The calculated volume of Vimizim from the appropriate number of vials is slowly withdrawn using caution to avoid excessive agitation.
Vimizim may be started at as young as an age possible
Vimizim contains an enzyme called elosulfase alfa,
Discuss with your doctor if the benefits of taking Vimizim are greater than the potential risk to your newborn while breast-feeding.
In clinical trials, spinal/cervical cord compression(SCC) was observed both in patients receiving Vimizim and patients receiving placebo.
The volume of Vimizim is to be slowly added to the sodium chloride 9 mg/ml(0.9%) solution for infusion.
The majority of patients who received Vimizim during clinical studies were in the paediatric and adolescent age range 5 to 17 years.

